Drug Topics June 11, 2024
Killian Meara

The Lingo and Libre Rio from Abbott are based on the company’s FreeStyle Libre sensing technology.

The FDA has provided clearance to 2 over-the-counter (OTC) continuous glucose monitor (CGM) systems, health care technology company Abbott announced in a release.1 The new OTC devices are based on the company’s FreeStyle Libre sensing technology, which is the most widely used CGM system in the world.

The Lingo and Libre Rio were both designed to meet different consumer needs. The Lingo aims to help adults gain a better understanding of their health and improve wellness, while the Libre Rio is for adults with type 2 diabetes (T2D) who do not use insulin and typically manage their disease through lifestyle modifications. The approval for...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, FDA, Govt Agencies, Medical Devices, Technology, Wearables
Trump names nominees to lead CDC, FDA, and his pick for surgeon general
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose
New FDA Panel Weighs In on Regulating Generative AI in Healthcare
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA
Trump's FDA Pick Is MedPage Today's Former Top Editor

Share This Article